parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in myonuclei	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	3 Parkinson's papers of 543	0.82
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 7205

receipt 7213: CDH13 in dopamine neurons, braak

power: full sample +0.22 (p 0.374, n 18), 95% CI -0.27 to +0.62. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.18 (p 0.482, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.735, n 18). could be the mix.
skeptic: leave-one-out range +0.13 to +0.37, sign flips 0; without severely affected donors +0.22 (p 0.374, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CDH13 in dopamine neurons.

case closed: nothing better to follow up.

receipt 7212: CDH13 in oligodendrocytes, braak

power: full sample -0.09 (p 0.735, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.02 (p 0.949, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.19 (p 0.450, n 18). could be the mix.
skeptic: leave-one-out range -0.19 to +0.04, sign flips 3; without severely affected donors -0.09 (p 0.735, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CDH13 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts